Open
Do GIP/GLP-1 & amylin agonists cause more hypoglycaemia than other treatments?
Also asked versus placebo.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
A coin flip. So far, the results disagree.
NoUnsureYes
- Belief
- 0.50 (range 0.00–0.55)
- Trials for
- 3
- Trials against
- 1
- Inconclusive
- 1
Already under way
No registered trial that could settle this is recruiting or active.
The evidence so far
- Registered trials
- 35
- With posted results
- 14
- Published papers
- 1
Of 39 decided analyses: 3 favor gip/glp-1 & amylin agonists, 21 find no difference, 15 favor the comparator.
Papers
- A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?Meta-analysis / systematic review · 2023
Trials
- A Randomized, Placebo-Controlled, Crossover Study to Investigate the Effect of Once-Weekly Tirzepatide on the Counter-Regulatory Response to Hypoglycemia in Patients With Type 2 Diabetes MellitusNCT04050553 · 10 posted results
- A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 DiabetesNCT05564039 · 1 posted result
- A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 DiabetesNCT03882970 · 10 posted results
- A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a SulfonylureaNCT04093752 · 10 posted results
- A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)NCT04537923 · 3 posted results
- A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 DiabetesNCT03987919 · 10 posted results
- Fully Closed-Loop Glucose Control in Adults With Type 1 Diabetes Using Tirzepatide: a Randomized, Multi-center, Open-label, Non-inferiority, Parallel TrialNCT07284511
- Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide: A Multicenter, Prospective, Randomized Controlled Trial (IIT)NCT07713992